ABVC BioPharma Announces Share Dividend to Reward Shareholders, Signaling Confidence in Subsidiary Growth

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has taken a significant step towards rewarding its shareholders by announcing a share dividend plan. This move involves distributing one share of AiBtl BioPharma Inc., a subsidiary of ABVC, for each share of ABVC common stock owned by the shareholder. This initiative is expected to distribute approximately 15 million AIBTL shares, pending the inclusion of these shares in an effective registration statement under the Securities Act of 1933.

This dividend distribution is a first for ABVC BioPharma and is seen as a strategic move to boost shareholder confidence and trust in the company's capabilities. Dr. Uttam Patil, ABVC's Chief Executive Officer, expressed pride in the company's journey and its ability to reward shareholders, highlighting the distribution as a testament to ABVC's confidence in AiBtl's long-term potential and commitment to shareholder value.

AiBtl BioPharma Inc., in which ABVC holds a 57.8% majority stake, is focused on developing botanical-based therapeutic candidates for central nervous system disorders, including major depressive disorder and attention deficit hyperactivity disorder. The partnership between ABVC and AiBtl is anticipated to enhance ABVC's strategic objectives in international business development, particularly in the Asia-Pacific markets, and establish collaborations with global pharmaceutical companies.

The announcement underscores ABVC BioPharma's growth trajectory and its efforts to leverage its subsidiaries and partnerships to expand its footprint in the biopharmaceutical industry. By distributing shares of AiBtl, ABVC not only rewards its shareholders but also signals its belief in the subsidiary's potential to contribute significantly to the company's future success. This move could have broader implications for the biopharmaceutical sector, particularly in the development of treatments for CNS disorders, and may influence investor perceptions of ABVC's long-term value and strategic direction.